Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts
Portfolio Pulse from Benzinga Insights
Seven analysts have recently evaluated 4D Molecular Therapeutics (NASDAQ:FDMT), with ratings ranging from bullish to bearish. The average 12-month price target is $45.43, up from $41.17 previously. Analysts' actions include maintaining, raising, and lowering ratings and price targets. The company faces challenges in revenue growth and profitability but has a strong ROE and low debt-to-equity ratio.
June 26, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
4D Molecular Therapeutics (NASDAQ:FDMT) has received mixed analyst ratings, with an average 12-month price target of $45.43. The company faces significant revenue and profitability challenges but has a strong ROE and low debt-to-equity ratio.
The mixed analyst ratings and the increase in the average price target suggest a neutral short-term impact. The company's financial challenges are balanced by its strong ROE and low debt, leading to a neutral outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100